Literature DB >> 26679751

Activation of liver X receptor/retinoid X receptor pathway ameliorates liver disease in Atp7B(-/-) (Wilson disease) mice.

James P Hamilton1, Lahari Koganti1, Abigael Muchenditsi2, Venkata S Pendyala2, David Huso3, Joseph Hankin4, Robert C Murphy4, Dominik Huster5, Uta Merle6, Christopher Mangels2, Nan Yang2, James J Potter1, Esteban Mezey1, Svetlana Lutsenko1,2.   

Abstract

UNLABELLED: Wilson disease (WD) is a hepatoneurological disorder caused by mutations in the copper-transporter, ATP7B. Copper accumulation in the liver is a hallmark of WD. Current therapy is based on copper chelation, which decreases the manifestations of liver disease, but often worsens neurological symptoms. We demonstrate that in Atp7b(-/-) mice, an animal model of WD, liver function can be significantly improved without copper chelation. Analysis of transcriptional and metabolic changes in samples from WD patients and Atp7b(-/-) mice identified dysregulation of nuclear receptors (NRs), especially the liver X receptor (LXR)/retinoid X receptor heterodimer, as an important event in WD pathogenesis. Treating Atp7b(-/-) mice with the LXR agonist, T0901317, ameliorated disease manifestations despite significant copper overload. Genetic markers of liver fibrosis and inflammatory cytokines were significantly decreased, lipid profiles normalized, and liver function and histology were improved.
CONCLUSIONS: The results demonstrate the major role of an altered NR function in the pathogenesis of WD and suggest that modulation of NR activity should be explored as a supplementary approach to improving liver function in WD. (Hepatology 2016;63:1828-1841).
© 2015 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26679751      PMCID: PMC4874878          DOI: 10.1002/hep.28406

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  39 in total

1.  High copper selectively alters lipid metabolism and cell cycle machinery in the mouse model of Wilson disease.

Authors:  Dominik Huster; Tina D Purnat; Jason L Burkhead; Martina Ralle; Oliver Fiehn; Franziska Stuckert; N Erik Olson; Daniel Teupser; Svetlana Lutsenko
Journal:  J Biol Chem       Date:  2007-01-07       Impact factor: 5.157

2.  Consequences of copper accumulation in the livers of the Atp7b-/- (Wilson disease gene) knockout mice.

Authors:  Dominik Huster; Milton J Finegold; Clinton T Morgan; Jason L Burkhead; Randal Nixon; Scott M Vanderwerf; Conrad T Gilliam; Svetlana Lutsenko
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

Review 3.  Mechanisms of hepatic fibrogenesis.

Authors:  Scott L Friedman
Journal:  Gastroenterology       Date:  2008-05       Impact factor: 22.682

4.  High glucose-induced repression of RAR/RXR in cardiomyocytes is mediated through oxidative stress/JNK signaling.

Authors:  Amar B Singh; Rakeshwar S Guleria; Irina T Nizamutdinova; Kenneth M Baker; Jing Pan
Journal:  J Cell Physiol       Date:  2012-06       Impact factor: 6.384

5.  Taurine is a liver X receptor-α ligand and activates transcription of key genes in the reverse cholesterol transport without inducing hepatic lipogenesis.

Authors:  Minh-Hien Hoang; Yaoyao Jia; Hee-jin Jun; Ji Hae Lee; Kwang-Yeon Hwang; Dal-Woong Choi; Soo-Jong Um; Boo-Yong Lee; Sang-Guan You; Sung-Joon Lee
Journal:  Mol Nutr Food Res       Date:  2012-06       Impact factor: 5.914

6.  Decreased serum antioxidant capacity in patients with Wilson disease is associated with neurological symptoms.

Authors:  Radan Bruha; Libor Vitek; Zdenek Marecek; Lenka Pospisilova; Sona Nevsimalova; Pavel Martasek; Jaromir Petrtyl; Petr Urbanek; Alena Jiraskova; Ivana Malikova; Martin Haluzik; Peter Ferenci
Journal:  J Inherit Metab Dis       Date:  2011-12-03       Impact factor: 4.982

7.  Abnormal hepatobiliary and circulating lipid metabolism in the Long-Evans Cinnamon rat model of Wilson's disease.

Authors:  Emile Levy; Sylvain Brunet; Fernando Alvarez; Ernest Seidman; Guylaine Bouchard; Enrique Escobar; Steve Martin
Journal:  Life Sci       Date:  2007-01-20       Impact factor: 5.037

8.  n-3 fatty acids ameliorate hepatic steatosis and dysfunction after LXR agonist ingestion in mice.

Authors:  Un Ju Jung; Peri N Millman; Alan R Tall; Richard J Deckelbaum
Journal:  Biochim Biophys Acta       Date:  2011-06-13

9.  Ursodeoxycholic acid inhibits liver X receptor α-mediated hepatic lipogenesis via induction of the nuclear corepressor SMILE.

Authors:  Ji-Min Lee; Gil-Tae Gang; Don-Kyu Kim; Yong Deuk Kim; Seung-Hoi Koo; Chul-Ho Lee; Hueng-Sik Choi
Journal:  J Biol Chem       Date:  2013-11-21       Impact factor: 5.157

10.  Resveratrol suppresses T0901317-induced hepatic fat accumulation in mice.

Authors:  Mingming Gao; Dexi Liu
Journal:  AAPS J       Date:  2013-04-17       Impact factor: 4.009

View more
  28 in total

Review 1.  Update on the Diagnosis and Management of Wilson Disease.

Authors:  Eve A Roberts
Journal:  Curr Gastroenterol Rep       Date:  2018-11-05

2.  Targeted inactivation of copper transporter Atp7b in hepatocytes causes liver steatosis and obesity in mice.

Authors:  Abigael Muchenditsi; Haojun Yang; James P Hamilton; Lahari Koganti; Franck Housseau; Lisa Aronov; Hongni Fan; Hannah Pierson; Ashima Bhattacharjee; Robert Murphy; Cynthia Sears; James Potter; Clavia R Wooton-Kee; Svetlana Lutsenko
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-04-20       Impact factor: 4.052

Review 3.  Wilson disease.

Authors:  Anna Członkowska; Tomasz Litwin; Petr Dusek; Peter Ferenci; Svetlana Lutsenko; Valentina Medici; Janusz K Rybakowski; Karl Heinz Weiss; Michael L Schilsky
Journal:  Nat Rev Dis Primers       Date:  2018-09-06       Impact factor: 52.329

Review 4.  Animal models of Wilson disease.

Authors:  Emily Reed; Svetlana Lutsenko; Oliver Bandmann
Journal:  J Neurochem       Date:  2018-06-26       Impact factor: 5.372

5.  The Function of ATPase Copper Transporter ATP7B in Intestine.

Authors:  Hannah Pierson; Abigael Muchenditsi; Byung-Eun Kim; Martina Ralle; Nicholas Zachos; Dominik Huster; Svetlana Lutsenko
Journal:  Gastroenterology       Date:  2017-09-25       Impact factor: 22.682

6.  Metabolic dysregulation in the Atp7b -/- Wilson's disease mouse model.

Authors:  Clavia Ruth Wooton-Kee; Matthew Robertson; Ying Zhou; Bingning Dong; Zhen Sun; Kang Ho Kim; Hailan Liu; Yong Xu; Nagireddy Putluri; Pradip Saha; Cristian Coarfa; David D Moore; Alli M Nuotio-Antar
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-10       Impact factor: 11.205

7.  Single nucleotide polymorphisms in the human ATP7B gene modify the properties of the ATP7B protein.

Authors:  Courtney J McCann; Samuel Jayakanthan; Mariacristina Siotto; Nan Yang; Maria Osipova; Rosanna Squitti; Svetlana Lutsenko
Journal:  Metallomics       Date:  2019-06-19       Impact factor: 4.526

8.  Adipocyte-specific disruption of ATPase copper transporting α in mice accelerates lipoatrophy.

Authors:  Cong Tao; Yajun Wang; Ying Zhao; Jianfei Pan; Yiping Fan; Xiaojuan Liang; Chunwei Cao; Jianguo Zhao; Michael J Petris; Kui Li; Yanfang Wang
Journal:  Diabetologia       Date:  2019-08-08       Impact factor: 10.122

9.  Altered zinc balance in the Atp7b-/- mouse reveals a mechanism of copper toxicity in Wilson disease.

Authors:  Kelsey A Meacham; María Paz Cortés; Eve M Wiggins; Alejandro Maass; Mauricio Latorre; Martina Ralle; Jason L Burkhead
Journal:  Metallomics       Date:  2018-11-14       Impact factor: 4.526

10.  Wilson Disease: Epigenetic effects of choline supplementation on phenotype and clinical course in a mouse model.

Authors:  Valentina Medici; Dorothy A Kieffer; Noreene M Shibata; Harpreet Chima; Kyoungmi Kim; Angela Canovas; Juan F Medrano; Alma D Islas-Trejo; Kusum K Kharbanda; Kristin Olson; Ruijun J Su; Mohammad S Islam; Raisa Syed; Carl L Keen; Amy Y Miller; John C Rutledge; Charles H Halsted; Janine M LaSalle
Journal:  Epigenetics       Date:  2016-09-09       Impact factor: 4.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.